Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
89bio, Inc. (ETNB)  
$8.86 0.11 (1.26%) as of 4:30 Thu 5/2


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 97,871,000
Market Cap: 867.14(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.66 - $22.03
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 20.2
Insider 6 Months    : 20.2
Insider 3/6 Months : 40.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,350,000 1,350,000 1,350,000 7,862,717
Total Buy Value $20,722,500 $20,722,500 $20,722,500 $80,687,796
Total People Bought 1 1 1 2
Total Buy Transactions 1 1 1 5
Total Shares Sold 57,195 107,195 154,628 206,908
Total Sell Value $623,326 $1,183,326 $2,078,063 $2,842,845
Total People Sold 1 1 4 5
Total Sell Transactions 2 3 7 15
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 89
  Page 2 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Martins Ryan Chief Financial Officer   •       –      –    2023-01-03 4 AS $12.51 $74,397 D/D (5,947) 36,368 50%     
   Mansbach Harry H Chief Medical Officer   •       –      –    2022-11-15 4 D $9.79 $30,476 D/D (3,113) 68,838     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2022-11-15 4 A $0.00 $0 D/D 9,000 71,951     -
   Shah Rajeev M. Director   –       •       •   2022-10-18 4 B $7.65 $8,971,469 I/I 1,172,741 8,955,410 2.25 53%     
   Le-Nguyen Quoc See Remarks   •       –      –    2022-09-30 4 D $5.79 $7,510 D/D (1,297) 65,404     -
   Le-Nguyen Quoc See Remarks   •       –      –    2022-09-30 4 A $0.00 $0 D/D 3,750 66,701     -
   Martins Ryan Chief Financial Officer   •       –      –    2022-09-28 4 D $5.76 $11,624 D/D (2,018) 42,315     -
   Martins Ryan Chief Financial Officer   •       –      –    2022-09-28 4 A $0.00 $0 D/D 5,833 44,333     -
   Palekar Rohan Chief Executive Officer   •       •      –    2022-09-28 4 D $5.76 $66,396 D/D (11,527) 219,429     -
   Palekar Rohan Chief Executive Officer   •       •      –    2022-09-28 4 A $0.00 $0 D/D 33,333 230,956     -
   Le-Nguyen Quoc See Remarks   •       –      –    2022-09-28 4 D $5.76 $16,600 D/D (2,882) 62,951     -
   Le-Nguyen Quoc See Remarks   •       –      –    2022-09-28 4 A $0.00 $0 D/D 8,333 65,833     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2022-09-28 4 D $5.76 $16,600 D/D (2,882) 62,951     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2022-09-28 4 A $0.00 $0 D/D 8,333 65,833     -
   Mansbach Harry H Chief Medical Officer   •       –      –    2022-09-09 4 A $0.00 $0 D/D 25,000 57,500     -
   Martins Ryan Chief Financial Officer   •       –      –    2022-09-09 4 A $0.00 $0 D/D 15,000 38,500     -
   Le-Nguyen Quoc See Remarks   •       –      –    2022-09-09 4 A $0.00 $0 D/D 25,000 57,500     -
   Palekar Rohan Chief Executive Officer   •       •      –    2022-09-08 4 OE $1.93 $193,000 D/D 100,000 197,623     -
   Shah Rajeev M. Director   –       •       •   2022-07-01 4 B $3.55 $9,999,995 I/I 2,816,900 7,782,669 2.25 163%     
   Hayden Michael R   –       •      –    2022-04-25 4 B $2.67 $26,700 I/I 10,000 103,978 0.01 70%     
   Hayden Michael R   –       •      –    2022-04-07 4 B $3.48 $34,750 I/I 10,000 93,978 0.01 51%     
   Hayden Michael R   –       •      –    2022-03-30 4 B $3.62 $22,625 I/I 6,250 83,978 0.01 16%     
   Palekar Rohan Chief Executive Officer   •       •      –    2022-02-17 4 A $0.00 $0 D/D 54,200 100,045     -
   Martins Ryan Chief Financial Officer   •       –      –    2022-02-17 4 A $0.00 $0 D/D 16,000 23,500     -
   Waisbourd Ram See Remarks   •       –      –    2022-02-17 4 A $0.00 $0 D/D 8,750 8,750     -
  89 Records found
  1  2  3  4   
  Page 2 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us